Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
Pharmaceutical giant Eli Lilly has partnered with AbCellera Biologics, a biotechnology company based in Canada, to address the new coronavirus crisis by developing antibody products to treat and prevent the virus.
Scientists from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health have begun a Phase 1 clinical trial for a vaccine to protect against the new coronavirus, COVID-19.
One algorithmic approach used to model and analyze complex networks is fundamentally flawed and fails to capture the full properties of real-world complexities, according to a new study published in Proceedings of the National Academy of Sciences.
As the U.S. continues ramping up its response to the new coronavirus, COVID-19, the role of AI could loom large in helping identify the highest risk patients.
Researchers have located the part of the brain that causes pediatric patients to stop breathing during a seizure, sharing their findings in JCI Insight.
Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.
The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals.
As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”
